Display options
Cite
Fiala M, Swartz J, Teklehaimanot S, et al. Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset. Lymphology. 1997;30(3):128-36
Fiala, M., Swartz, J., Teklehaimanot, S., Kermani, V., Funnye, A. S., Sayre, J. W., & Gornbein, J. A. (1997). Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset. Lymphology, 30(3), 128-36.
Fiala, M, et al. "Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset." Lymphology vol. 30,3 (1997): 128-36.
Fiala M, Swartz J, Teklehaimanot S, Kermani V, Funnye AS, Sayre JW, Gornbein JA. Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset. Lymphology. 1997 Sep;30(3):128-36. PMID: 9313205.
Copy Download .nbib Format: NLM
Share it on

Lymphology. 1997 Sep;30(3):128-36.

Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset.

Lymphology

M Fiala, J Swartz, S Teklehaimanot, V Kermani, A S Funnye, J W Sayre, J A Gornbein

Affiliations

  1. Department of Medicine, UCLA School of Medicine, USA.

PMID: 9313205

Abstract

In 60 patients followed from the onset of acquired immunodeficiency syndrome (AIDS) to death, survival was determined by Cox Proportional Hazards Analysis in relationship to seven variables: time-dependent CD4+ and CD8+ peripheral lymphocyte counts, zidovudine treatment, cytomegalovirus (CMV) retinitis, time from AIDS onset, calendar year of AIDS onset (cohort effect), and age. Two significant prognostic variables were identified: zidovudine therapy and either CD4+ or CD8+ counts (the latter could not be distinguished due to concomitant high correlation). Treatment with zidovudine reduced the death rate by 75% compared to no treatment. When included in a proportional hazards regression with all covariates except for the other T lymphocyte count, every increase in CD4+ count of 10 cells was equivalent to a decline in the mortality rate by 13% (p = 0.046), and every increase in CD8+ count of 10 cells lowered the mortality by 1.4% (p = 0.0031). Patients treated with zidovudine and without CMV retinitis showed the slowest decline of both CD4+ and CD8+ counts. Both CD4+ and CD8+ levels are useful predictors of survival in patients with AIDS.

Substances

MeSH terms

Publication Types

Grant support